S100A8 enhances osteoclastic bone resorption in vitro through activation of Toll-like receptor 4: Implications for bone destruction in murine antigen-induced arthritis

Arthritis and Rheumatism

Volumn 63, Issue 5, 2011, Pages 1365-1375

  Grevers, Lilyanne C ^a   De Vries, Teun J ^b   Vogl, Thomas ^c   Abdollahi Roodsaz, Shahla ^a   Sloetjes, Annet W ^a   Leenen, Pieter J M ^d   Roth, Johannes ^c   Everts, Vincent ^b   Van Den Berg, Wim B ^a   Van Lent, Peter L E M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR ANTIBODY; CALGRANULIN A; CALGRANULIN B; CATHEPSIN K; F ACTIN; RECEPTOR ANTIBODY; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BONE ATROPHY; BONE DESTRUCTION; BONE EROSION; CELL DIFFERENTIATION; CONTROLLED STUDY; IN VITRO STUDY; KNEE ARTHRITIS; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL; WILD TYPE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BONE AND BONES; BONE RESORPTION; CALGRANULIN A; CATHEPSIN K; KNEE JOINT; MICE; MICE, KNOCKOUT; OSTEOCLASTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 79955555208     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30290     Document Type: Article

References (48)

1. Goldring SR, Gravallese EM,. Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 2000; 12: 195-9. (Pubitemid 30238387)
2. McInnes IB, Schett G,. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007; 7: 429-42. (Pubitemid 46834849)
3. Ehrchen JM, Sunderkotter C, Foell D, Vogl T, Roth J,. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 2009; 86: 557-66.
4. Baillet A, Trocme C, Berthier S, Arlotto M, Grange L, Chenau J, et al. Synovial fluid proteomic fingerprint: S100A8, S100A9 and S100A12 proteins discriminate rheumatoid arthritis from other inflammatory joint diseases. Rheumatology (Oxford) 2010; 49: 671-82.
5. Hammer HB, Odegard S, Syversen SW, Landewe R, van der Heijde D, Uhlig T, et al. Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69: 150-4.
6. Hammer HB, Odegard S, Fagerhol MK, Landewe R, van der Heijde D, Uhlig T, et al. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 1093-7. (Pubitemid 47122325)
7. Manitz MP, Horst B, Seeliger S, Strey A, Skryabin BV, Gunzer M, et al. Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro. Mol Cell Biol 2003; 23: 1034-43. (Pubitemid 36133519)
8. Hobbs JA, May R, Tanousis K, McNeill E, Mathies M, Gebhardt C, et al. Myeloid cell function in MRP-14 (S100A9) null mice. Mol Cell Biol 2003; 23: 2564-76. (Pubitemid 36351035)
9. Perera C, McNeil HP, Geczy CL,. S100 calgranulins in inflammatory arthritis. Immunol Cell Biol 2010; 88: 41-9.
10. Foell D, Wittkowski H, Vogl T, Roth J,. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007; 81: 28-37. (Pubitemid 46021248)
11. Ghavami S, Rashedi I, Dattilo BM, Eshraghi M, Chazin WJ, Hashemi M, et al. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukoc Biol 2008; 83: 1484-92. (Pubitemid 351960330)
12. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007; 13: 1042-9. (Pubitemid 47517513)
13. Foell D, Wittkowski H, Roth J,. Mechanisms of disease: a 'DAMP' view of inflammatory arthritis. Nat Clin Pract Rheumatol 2007; 3: 382-90. (Pubitemid 47034539)
14. Zhou Z, Immel D, Xi CX, Bierhaus A, Feng X, Mei L, et al. Regulation of osteoclast function and bone mass by RAGE. J Exp Med 2006; 203: 1067-80.
15. Nakamura H, Fukusaki Y, Yoshimura A, Shiraishi C, Kishimoto M, Kaneko T, et al. Lack of Toll-like receptor 4 decreases lipopolysaccharide-induced bone resorption in C3H/HeJ mice in vivo. Oral Microbiol Immunol 2008; 23: 190-5. (Pubitemid 351519448)
16. Van Lent PL, Grevers LC, Blom AB, Sloetjes A, Mort JS, Vogl T, et al. Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis. Ann Rheum Dis 2008; 67: 1750-8.
17. Zreiqat H, Howlett CR, Gronthos S, Hume D, Geczy CL,. S100A8/S100A9 and their association with cartilage and bone. J Mol Histol 2007; 38: 381-91. (Pubitemid 350056770)
18. Hunter MJ, Chazin WJ,. High level expression and dimer characterization of the S100 EF-hand proteins, migration inhibitory factor-related proteins 8 and 14. J Biol Chem 1998; 273: 12427-35. (Pubitemid 28240615)
19. Hsieh HL, Schafer BW, Weigle B, Heizmann CW,. S100 protein translocation in response to extracellular S100 is mediated by receptor for advanced glycation endproducts in human endothelial cells. Biochem Biophys Res Commun 2004; 316: 949-59. (Pubitemid 38368045)
20. De Vries TJ, Schoenmaker T, Beertsen W, van der Neut R, Everts V,. Effect of CD44 deficiency on in vitro and in vivo osteoclast formation. J Cell Biochem 2005; 94: 954-66. (Pubitemid 41420256)
21. De Bruijn MF, Slieker WA, van der Loo JC, Voerman JS, van Ewijk W, Leenen PJ,. Distinct mouse bone marrow macrophage precursors identified by differential expression of ER-MP12 and ER-MP20 antigens. Eur J Immunol 1994; 24: 2279-84. (Pubitemid 24303066)
22. Piper K, Boyde A, Jones SJ,. The relationship between the number of nuclei of an osteoclast and its resorptive capability in vitro. Anat Embryol (Berl) 1992; 186: 291-9.
23. De Vries TJ, Schoenmaker T, Hooibrink B, Leenen PJ, Everts V,. Myeloid blasts are the mouse bone marrow cells prone to differentiate into osteoclasts. J Leukoc Biol 2009; 85: 919-27.
24. Vaananen HK, Zhao H, Mulari M, Halleen JM,. The cell biology of osteoclast function. J Cell Sci 2000; 113: 377-81. (Pubitemid 30116644)
25. Gravallese EM,. Bone destruction in arthritis. Ann Rheum Dis 2002; 61 Suppl II: ii84-6. (Pubitemid 35221724)
26. Nabbe KC, Blom AB, Holthuysen AE, Boross P, Roth J, Verbeek S, et al. Coordinate expression of activating Fcγ receptors I and III and inhibiting Fcγ receptor type II in the determination of joint inflammation and cartilage destruction during immune complex-mediated arthritis. Arthritis Rheum 2003; 48: 255-65. (Pubitemid 36091671)
27. Van Lent PL, Nabbe K, Blom AB, Holthuysen AE, Sloetjes A, van de Putte LB, et al. Role of activatory FcγRI and FcγRIII and inhibitory FcγRII in inflammation and cartilage destruction during experimental antigen-induced arthritis. Am J Pathol 2001; 159: 2309-20. (Pubitemid 33104284)
28. Van Lent PL, Grevers LC, Schelbergen R, Blom A, Geurts J, Sloetjes A, et al. S100A8 causes a shift toward expression of activatory Fcγ receptors on macrophages via Toll-like receptor 4 and regulates Fcγ receptor expression in synovium during chronic experimental arthritis. Arthritis Rheum 2010; 62: 3353-64.
29. Song I, Kim JH, Kim K, Jin HM, Youn BU, Kim N,. Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation. FEBS Lett 2009; 583: 2435-40.
30. Takayanagi H,. The role of NFAT in osteoclast formation. Ann N Y Acad Sci 2007; 1116: 227-37. (Pubitemid 350274348)
31. Miyamoto T,. The dendritic cell-specific transmembrane protein DC-STAMP is essential for osteoclast fusion and osteoclast bone-resorbing activity. Mod Rheumatol 2006; 16: 341-2. (Pubitemid 44921579)
32. Ek-Rylander B, Andersson G,. Osteoclast migration on phosphorylated osteopontin is regulated by endogenous tartrate-resistant acid phosphatase. Exp Cell Res 2010; 316: 443-51.
33. Zaidi M, Blair HC, Moonga BS, Abe E, Huang CL,. Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. J Bone Miner Res 2003; 18: 599-609. (Pubitemid 36899309)
34. Fletcher DA, Mullins RD,. Cell mechanics and the cytoskeleton. Nature 2010; 463: 485-92.
35. Teitelbaum SL,. Bone resorption by osteoclasts. Science 2000; 289: 1504-8.
36. Vogl T, Ludwig S, Goebeler M, Strey A, Thorey IS, Reichelt R, et al. MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood 2004; 104: 4260-8. (Pubitemid 39620181)
37. Lominadze G, Rane MJ, Merchant M, Cai J, Ward RA, McLeish KR,. Myeloid-related protein-14 is a p38 MAPK substrate in human neutrophils. J Immunol 2005; 174: 7257-67. (Pubitemid 40705695)
38. Goebeler M, Roth J, van den Bos C, Ader G, Sorg C,. Increase of calcium levels in epithelial cells induces translocation of calcium-binding proteins migration inhibitory factor-related protein 8 (MRP8) and MRP14 to keratin intermediate filaments. Biochem J 1995; 309: 419-24.
39. Roth J, Burwinkel F, van den Bos C, Goebeler M, Vollmer E, Sorg C,. MRP8 and MRP14, S-100-like proteins associated with myeloid differentiation, are translocated to plasma membrane and intermediate filaments in a calcium-dependent manner. Blood 1993; 82: 1875-83. (Pubitemid 23278779)
40. Rajachar RM, Truong AQ, Giachelli CM,. The influence of surface mineral and osteopontin on the formation and function of murine bone marrow-derived osteoclasts. J Mater Sci Mater Med 2008; 19: 3279-85.
41. Takahashi N, Ejiri S, Yanagisawa S, Ozawa H,. Regulation of osteoclast polarization. Odontology 2007; 95: 1-9.
42. Teitelbaum SL, Ross FP,. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003; 4: 638-49. (Pubitemid 36917505)
43. Nakamura I, Takahashi N, Sasaki T, Jimi E, Kurokawa T, Suda T,. Chemical and physical properties of the extracellular matrix are required for the actin ring formation in osteoclasts. J Bone Miner Res 1996; 11: 1873-9. (Pubitemid 26425679)
44. Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J, et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 2008; 29: 2035-43.
45. Abdollahi-Roodsaz S, Joosten LA, Roelofs MF, Radstake TR, Matera G, Popa C, et al. Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum 2007; 56: 2957-67. (Pubitemid 47502742)
46. Abdollahi-Roodsaz S, Joosten LA, Helsen MM, Walgreen B, van Lent PL, van den Bersselaar LA, et al. Shift from Toll-like receptor 2 (TLR-2) toward TLR-4 dependency in the erosive stage of chronic streptococcal cell wall arthritis coincident with TLR-4-mediated interleukin-17 production. Arthritis Rheum 2008; 58: 3753-64.
47. Soysa NS, Alles N, Shimokawa H, Jimi E, Aoki K, Ohya K,. Inhibition of the classical NF-γ B pathway prevents osteoclast bone-resorbing activity. J Bone Miner Metab 2009; 27: 131-9.
48. Xing L, Bushnell TP, Carlson L, Tai Z, Tondravi M, Siebenlist U, et al. NF-γ B p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J Bone Miner Res 2002; 17: 1200-10. (Pubitemid 34680496)